{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T00:59:21Z","timestamp":1780448361129,"version":"3.54.1"},"reference-count":18,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T00:00:00Z","timestamp":1645660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Chronic actinic dermatitis (CAD) is a rare chronic immunological photo-dermatosis resulting in pruritic eczematous eruption on sun-exposed skin to ultraviolet (UV) light. The disease mechanism may include a delay-type hypersensitivity reaction to an endogenous photo-induced antigen, postulated to be UVR-altered DNA, but the exact pathophysiology is unknown. Minimum erythema dosing and patch testing are diagnostic tools of CAD. There are limited safe and effective treatment options for CAD. Herein, a case series of three patients with severe recalcitrant CAD is presented after being treated with dupilumab off-label. The patients in this study had persistent severe disease and taken the first-line management plan, which consists of topical calcineurin inhibitors (TCI), topical corticosteroids (TCS), and strict photoprotection. However, the above treatment options were not able to control the symptoms. The patients were treated with dupilumab 600 mg first dose, 300 mg biweekly subcutaneously (SC), and hydroxychloroquine. Dupilumab showed excellent clinical benefits, including safe and well-tolerated in chronic actinic dermatitis. Further studies are required to be carried out before being applied in clinical practice.<\/jats:p>","DOI":"10.3389\/fmed.2022.803692","type":"journal-article","created":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T06:53:25Z","timestamp":1645685605000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":20,"title":["Clearance of Chronic Actinic Dermatitis With Dupilumab Therapy in Chinese Patients: A Case Series"],"prefix":"10.3389","volume":"9","author":[{"given":"Kamran","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liming","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"HaiYue","family":"Lou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianbo","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"YunMi","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaYang","family":"Da","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JingPeng","family":"Shan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KaiNing","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.det.2014.03.007","article-title":"Chronic actinic dermatitis","author":"Paek","year":"2014","journal-title":"Dermatol Clin"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1001\/archderm.130.10.1284","article-title":"Chronic actinic dermatitis an analysis of 51 patients evaluated in the United States and Japan","volume":"130","author":"Lim","year":"1994","journal-title":"Arch Dermatol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/CE.S133661","article-title":"Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis","volume":"13","author":"Eshtiaghi","year":"2018","journal-title":"Core Evid."},{"key":"B4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1111\/j.1751-1097.1996.tb02454.x","article-title":"Does exposure to UV radiation induce a shift to a Th-2-like immune reaction?","volume":"64","author":"Ullrich","year":"1996","journal-title":"Photochem Photobiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.2310\/7750.2008.08018","article-title":"Chronic actinic dermatitis: clinical cases, diagnostic workup, therapeutic management","volume":"13","author":"Beach","year":"2009","journal-title":"J Cutan Med Surg."},{"key":"B6","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1111\/j.1600-0781.2004.00129.x","article-title":"Chronic actinic dermatitis","volume":"20","author":"Hawk","year":"2004","journal-title":"Photodermatol Photoimmunol Photomed."},{"key":"B7","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1111\/dth.12528","article-title":"Evaluation of narrow band ultraviolet B phototherapy in the treatment of chronic actinic dermatitis in Chinese patients","author":"Ma","year":"2017","journal-title":"Dermatol Ther"},{"key":"B8","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1111\/phpp.12566","article-title":"Dupilumab for the treatment of chronic actinic dermatitis","volume":"36","author":"Patel","year":"2020","journal-title":"Photodermatol Photoimmunol Photomed."},{"key":"B9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1177\/2050313X19845235","article-title":"A case report of therapeutically challenging chronic actinic dermatitis","author":"Verma","year":"2019","journal-title":"SAGE Open Med Case Rep"},{"key":"B10","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jdcr.2019.05.006","article-title":"Dupilumab for the treatment of severe photodermatitis","volume":"5","author":"Smith","year":"2019","journal-title":"JAAD Case Rep."},{"key":"B11","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1056\/NEJMoa1314768","article-title":"Dupilumab treatment in adults with moderate-to-severe atopic dermatitis","volume":"371","author":"Beck","year":"2014","journal-title":"N Engl J Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1111\/phpp.12244","article-title":"The clinical severity score of chronic actinic dermatitis correlates with in vivo photoallergic reactions and the immunologic parameters related to a shift towards Th2 immunity from the Th2\/Th1 balanced status in patients with chronic actinic dermatitis","volume":"32","author":"Ko","year":"2016","journal-title":"Photodermatol Photoimmunol Photomed"},{"key":"B13","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","article-title":"Pathophysiology of atopic dermatitis: clinical implications","volume":"40","author":"Kim","year":"2019","journal-title":"Allergy Asthma Proc."},{"key":"B14","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1002\/jlb.56.6.769","article-title":"The role of IL-4, IL-10, and TNF-alpha in the immune suppression induced by ultraviolet radiation","volume":"56","author":"Rivas","year":"1994","journal-title":"J Leukoc Biol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1046\/j.1365-2133.1998.02132.x","article-title":"The photosensitivity dermatitis and actinic reticuloid syndrome (chronic actinic dermatitis) occurring in seven young atopic dermatitis patients","volume":"138","author":"Russell","year":"1998","journal-title":"Br J Dermatol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1046\/j.1365-2133.1998.2576c.x","article-title":"Chronic actinic dermatitis occurring in young patients with atopic dermatitis","volume":"139","author":"Creamer","year":"1998","journal-title":"Br J Dermatol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1046\/j.1365-2133.2000.03457.x","article-title":"Chronic actinic dermatitis in young atopic dermatitis sufferers","volume":"142","author":"Ogboli","year":"2000","journal-title":"Br J Dermatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"453","DOI":"10.4103\/idoj.IDOJ_280_20","article-title":"Hydroxychloroquine in dermatology and beyond: recent update","volume":"11","author":"Sardana","year":"2020","journal-title":"Indian Dermatol Online J."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.803692\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,24]],"date-time":"2022-02-24T06:53:26Z","timestamp":1645685606000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2022.803692\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,24]]},"references-count":18,"alternative-id":["10.3389\/fmed.2022.803692"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2022.803692","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,24]]},"article-number":"803692"}}